Gregory S Calip1,2,3, John Kidd4, Ryan Bernhisel4, Hannah C Cox4, Jennifer Saam4, Garth H Rauscher5,6, Johnathan M Lancaster4,7, Kent F Hoskins5,8. 1. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 South Wood Street MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu. 2. University of Illinois Cancer Center, Chicago, IL, USA. gcalip@uic.edu. 3. Flatiron Health, New York, NY, USA. gcalip@uic.edu. 4. Myriad Genetics Laboratories, Inc, Salt Lake City, UT, USA. 5. University of Illinois Cancer Center, Chicago, IL, USA. 6. Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA. 7. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. 8. Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA.
Abstract
PURPOSE: The role of genetic predisposition in male breast cancer (MBC) patients who test negative for a BRCA mutation is unclear. The aim of this study is to define the association between MBC and family history of breast cancer in patients without mutations in BRCA1 or BRCA2. METHODS: We conducted an unmatched case-control study with men who received commercial testing for germline mutations in cancer susceptibility genes, including 3,647 MBC cases who tested negative for deleterious mutations in BRCA1/BRCA2, and 4,269 men with a personal history of colorectal cancer who tested negative for mutations in DNA mismatch repair genes to serve as controls. Associations between family history of breast cancer and MBC were estimated using unconditional multivariable logistic regression with adjustment for age, race/ethnicity and year of testing. RESULTS: Breast cancer in a first- or second-degree relative was associated with a four-fold increased odds of MBC (OR 4.7; 95% CI 4.1, 5.3). Associations with MBC were strongest for family history of breast cancer in 2 or more first-degree relatives (FDR) (OR 7.8; 95% CI 5.2, 11.6), for probands and FDR diagnosed at age < 45 years (OR 6.9; 95% CI 3.9, 12.4), and for family history of MBC (OR 17.9; 95% CI 7.6, 42.1). Findings were confirmed in a sensitivity analysis of MBC cases who tested negative on a 25-gene pan-cancer panel. CONCLUSIONS: MBC patients without mutations in BRCA1/2 have significantly higher odds of a family history of breast cancer, suggesting the existence of unidentified MBC susceptibility alleles.
PURPOSE: The role of genetic predisposition in male breast cancer (MBC) patients who test negative for a BRCA mutation is unclear. The aim of this study is to define the association between MBC and family history of breast cancer in patients without mutations in BRCA1 or BRCA2. METHODS: We conducted an unmatched case-control study with men who received commercial testing for germline mutations in cancer susceptibility genes, including 3,647 MBC cases who tested negative for deleterious mutations in BRCA1/BRCA2, and 4,269 men with a personal history of colorectal cancer who tested negative for mutations in DNA mismatch repair genes to serve as controls. Associations between family history of breast cancer and MBC were estimated using unconditional multivariable logistic regression with adjustment for age, race/ethnicity and year of testing. RESULTS: Breast cancer in a first- or second-degree relative was associated with a four-fold increased odds of MBC (OR 4.7; 95% CI 4.1, 5.3). Associations with MBC were strongest for family history of breast cancer in 2 or more first-degree relatives (FDR) (OR 7.8; 95% CI 5.2, 11.6), for probands and FDR diagnosed at age < 45 years (OR 6.9; 95% CI 3.9, 12.4), and for family history of MBC (OR 17.9; 95% CI 7.6, 42.1). Findings were confirmed in a sensitivity analysis of MBC cases who tested negative on a 25-gene pan-cancer panel. CONCLUSIONS: MBC patients without mutations in BRCA1/2 have significantly higher odds of a family history of breast cancer, suggesting the existence of unidentified MBC susceptibility alleles.
Entities:
Keywords:
BRCA1; BRCA2; Family history; Genetics; Male breast cancer
Authors: Harvey A Risch; John R McLaughlin; David E C Cole; Barry Rosen; Linda Bradley; Isabel Fan; James Tang; Song Li; Shiyu Zhang; Patricia A Shaw; Steven A Narod Journal: J Natl Cancer Inst Date: 2006-12-06 Impact factor: 13.506
Authors: R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem Journal: Nature Date: 1995 Dec 21-28 Impact factor: 49.962
Authors: F J Couch; L M Farid; M L DeShano; S V Tavtigian; K Calzone; L Campeau; Y Peng; B Bogden; Q Chen; S Neuhausen; D Shattuck-Eidens; A K Godwin; M Daly; D M Radford; S Sedlacek; J Rommens; J Simard; J Garber; S Merajver; B L Weber Journal: Nat Genet Date: 1996-05 Impact factor: 38.330
Authors: Louise A Brinton; Douglas A Richesson; Gretchen L Gierach; James V Lacey; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin Journal: J Natl Cancer Inst Date: 2008-10-07 Impact factor: 13.506